Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter November 17, 2018

Tramadol-induced parkinsonism: a case report of a 75-year-old woman

  • Ranbir Singh EMAIL logo

Abstract

Adverse drug reaction (ADR) is a form of unwanted reaction and is the crucial reason for illness and death. Tramadol-induced parkinsonism is a kind of ADR that occurs after the repeated intake of tramadol. Long-term exposure to tramadol has been known to induce tremor and alter the functioning of dopamine. This case report introduces a 75-year-old woman diagnosed with tramadol-induced parkinsonism due to the administration of tramadol for the treatment of post-operated (breast cancer) acute onset of severe pain on the left side of the chest. The assessment of the offending drug was carried out via Naranjo probability scale. A score of 6 was reported for this patient, defining tramadol as a probable cause of this reaction. For the management of the drug-induced parkinsonism, levodopa/carbidopa was prescribed and the symptoms related to parkinsonism resolved within a week. The age of the patient and the female gender is considered to be the main risk factor for the occurrence of such reaction. This case report is an attempt to spread awareness about the negative consequences of long-term use of tramadol in old patients. Thus, the medical practitioners must be very careful while administering tramadol to the old aged population.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Lopez-Sendon J, Mena MA, de Yebenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf 2013;12:487–96.10.1517/14740338.2013.787065Search in Google Scholar

2. Lopez-Sendon JL, Mena MA, de Yebenes JG. Drug-induced parkinsonism in the elderly: incidence, management, and prevention. Drugs Aging 2012;29:105–18.10.2165/11598540-000000000-00000Search in Google Scholar

3. Noyes K, Liu H, Holloway RG. What is the risk of developing parkinsonism following Neuroleptic use? Neurology 2006;66:941–3.10.1212/01.wnl.0000203348.13337.89Search in Google Scholar

4. Benito-León J, Bermejo-Pareja F, Rodríguez J, Molina JA, Gabriel R, Morales JM. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 2003;18:267–74.10.1002/mds.10362Search in Google Scholar

5. Wenning GK, Kiechl S, Seppi K, Müller J, Högl B, Saletu M, et al. Prevalence of movement disorders in men and women aged 50–89 years (Bruneck Study cohort): a population-based study. Lancet Neurol 2005;4:815–20.10.1016/S1474-4422(05)70226-XSearch in Google Scholar

6. Barbosa MT, Caramelli P, Maia DP, Cunningham MC, Guerra HL, Lima-Costa MF, et al. Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambuí study). Mov Disord 2006;21:800–8.10.1002/mds.20806Search in Google Scholar

7. Avorn J, Bohn RL, Mogun H, Gurwitz JH, Monane M, Everitt D, et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med 1995;99:48–54.10.1016/S0002-9343(99)80104-1Search in Google Scholar

8. Susatia F, Fernandez HH. Drug-induced parkinsonism. Curr Treat Options Neurol 2009;11:162–9.10.1007/s11940-009-0019-3Search in Google Scholar

9. Thanvi B, Treadwell S. Drug-induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 2009;85:322–6.10.1136/pgmj.2008.073312Search in Google Scholar

10. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, et al. Dopamine transporters decrease with age. J Nucl Med 1996;37:554–9.Search in Google Scholar

11. Bedard P, Langelier P, Villeneuve A. Oestrogens and extrapyramidal system. Lancet 1977;2:1367–8.10.1016/S0140-6736(77)90429-9Search in Google Scholar

12. Matthiesen T, Wöhrmann T, Coogan TP, Uragg H. The experimental toxicology of tramadol: an overview. Toxicol Lett 1993; 95:63–71.10.1016/S0378-4274(98)00023-XSearch in Google Scholar

13. Adams EH, Breiner S, Cicero TJ, Geller A, Inciardi JA, Schnoll SH, et al. A Comparison of the Abuse Liability of Tramadol, NSAIDs, and Hydrocodone in Patients with Chronic Pain. J Pain Symptom Manage 2006;31:465–76.10.1016/j.jpainsymman.2005.10.006Search in Google Scholar

14. Tarikka P, Tuominen M, Lindgren L. Comparison of respiratory effects of tramadol and oxycodone. J Clin Anesth 1997;9:582–5.10.1016/S0952-8180(97)00147-5Search in Google Scholar

15. Stadtland C, Erfurth A, Arolt V. De novo onset of Parkinson’s disease after antidepressant treatment with citalopram. J Clin Psychopharmacol 2000;20:581–2.10.1055/s-2000-7586Search in Google Scholar PubMed

16. Pina Latorre MA, Modrego PJ, Rodilla F, Catalán C, Calvo M. Parkinsonism and Parkinson’s disease associated with long-term administration of sertraline. J Clin Pharm Ther 2001;26:111–2.10.1046/j.1365-2710.2001.00307.xSearch in Google Scholar PubMed

17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:23–45.10.1038/clpt.1981.154Search in Google Scholar PubMed

18. Yalcin I, Aksu F, Bodard S, Chalon S, Belzung C. Antidepressant-like effect of tramadol in the unpredictable chronic mild stress procedure: possible involvement of the noradrenergic system. Behav Pharmacol 2007;18:623–31.10.1097/FBP.0b013e3282eff109Search in Google Scholar PubMed

19. Leo R. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57:449–54.10.4088/JCP.v57n1002Search in Google Scholar

20. Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Extrapyramidal symptoms associated with antidepressants – a review of literature and analysis of spontaneous reports. Ann Clin Psychiatry 2010;22:148–56.Search in Google Scholar

21. Miletic V, Relja M. Citalopram-induced parkinsonian syndrome: case report. Clin Neuropharmacol 2011;34:92–3.10.1097/WNF.0b013e318210ea3eSearch in Google Scholar PubMed

22. Gregory R, White J. Can sertraline induce Parkinson’s disease? Psychosomatics 2001;42:163–4.10.1176/appi.psy.42.2.163-aSearch in Google Scholar PubMed

23. Di Rocco A, Brannan T, Prikhojan A, Yahr M. Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm 1998;105:247–51.10.1007/s007020050053Search in Google Scholar PubMed

24. Gonul A, Aksu M. SSRI-induced parkinsonism may be an early sign of future Parkinson’s Disease. J Clin Psychiatry 1999;60:410.10.4088/JCP.v60n0611dSearch in Google Scholar

Received: 2018-06-26
Accepted: 2018-10-19
Published Online: 2018-11-17

©2019 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.1515/jbcpp-2018-0113/html
Scroll to top button